用以治療亨丁頓舞蹈症及癌症之雙重功能化合物
的設計與合成研究

陳志彬

3.239.51.78，Hello！

Close
Search Quick Search Advanced Search Publication Search	Personal Service Member Login Searching History Use Bonus Card SYMSKAN
Browse Browse by University of Graduate Thesis Browse by Pinyin of Graduate Thesis Browse by Conference Proceedings Topic Browse by Conference Proceedings Publisher Browse by Pinyin of Conference Proceedings Browse by eBook Category Browse by eBook Topic Browse by eBook Publisher
Customer Services Authorize Airiti Recommend a Journal

Search Symbol (Half-width)	Description of Search Symbols
Space	"AND" indicates the intertwining of key terms used in a search
Double Quotation Marks ("") ( " " )	Double quotation marks indicate the beginning and end of a phrase, and the search will only include terms that appear in the same order of those within the quotations. Example: "image process" ： " image process "
?	Indicates a variable letter. Entering two ? will indicate two variable letters, and so on. Example: "Appl?", search results will yield apple, apply… e , appl y … ( (often used to English word searches) )
*	Indicates an unlimited number of variable letters to follow, from 1~n. Example: Enter "appl*", search results will yield apple, apples, apply, applied, application…(often used in English word searches) e , appl es , appl y , appl ied , appl ication … ( (often used to English word searches) )
AND、OR、NOT	Boolean logic combinations of key words is a skill used to expand or refine search parameters. (1) AND (1) AND: Refines search parameters (2) OR (2) OR: Expands search parameters (3) NOT: Excludes irrelevant parameters

DOI stands for Digital Object Identifier （ D igital O bject I dentifier ） ,
and is the unique identifier for objects on the internet. It can be used to create persistent link and to cite articles.

Using DOI as a persistent link

To create a persistent link, add「http://dx.doi.org/」「 http://dx.doi.org/ 」 before a DOI.
For instance, if the DOI of an article is 10.5297/ser.1201.002 , you can link persistently to the article by entering the following link in your browser: http://dx.doi.org/ 10.5297/ser.1201.002 。
The DOI link will always direct you to the most updated article page no matter how the publisher changes the document's position, avoiding errors when engaging in important research.

Cite a document with DOI

When citing references, you should also cite the DOI if the article has one. If your citation guideline does not include DOIs, you may cite the DOI link.

DOIs allow accurate citations, improve academic contents connections, and allow users to gain better experience across different platforms. Currently, there are more than 70 million DOIs registered for academic contents. If you want to understand more about DOI, please visit airiti DOI Registration （ doi.airiti.com ）。

Data Source

Basic & Applied Sciences > Chemistry
College of Science > Graduate Institute of Chemistry

Bibliography Management Tool

Related Links

Report an Issue

Purchase Single Articles

Download PDF

用以治療亨丁頓舞蹈症及癌症之雙重功能化合物的設計與合成研究

Design and Synthesis of Dual-functional Compounds for Therapy of Huntington’s Disease and Cancers

陳志彬 , Ph.D　　Advisor：方俊民　　

英文

Adenosine receptor ； Equilibrative nucleoside transporter ；亨丁頓舞蹈症；腺嘌呤核苷受體；平衡型核苷轉運子

Abstract │ Reference (163) │ Altmetrics

Parallel Abstract 〈TOP〉

In 2007, N6-(4-hydroxybenzyl)adenosine (T1-11, 16) was found to exert dual functions, acting as an agonist of adenosine A2A receptor and as an inhibitor of adenosine transporter (ENT1). This cooperative function of T1-11 effectively amplifies the activation of adenosinergic system in synapses. Therefore, T1-11 has potential to be developed to treat Huntington’s disease. 
  The constructed dual-pharmacophore model based on the known ligand structures of A2A receptor and ENT1 suggested the derivatization of hydrophobic moieties at the 5′-position of the lead compound, T1-11, in addition to the modification of 6-NH2 group. Thus, a series of T1-11 analogues were synthesized, and their pharmacological properties and neuroprotective activities were subsequently examined respectively by competitive radioligand binding assay and PC12 cell survival assay. 
  These 5′-modified derivatives of T1-11 and its anisole analogue 19 generally showed somewhat decreased A2A agonism which accompanied by weaker neuroprotective activity. In contrast, these derivatives exhibited slightly better ENT1 inhibitory activity.
  Utilizing the fusing and merging strategies of the knowledge-based designed multiple ligands (DMLs) approach and Lipinski’s “Rule of Five”, we rationally designed the dual-functional compounds. We have synthesized a series of inhibitors and evaluated their biological activities, including the cytotoxicity and in vitro enzymatic and cell-based assays. All synthesized compounds, except for 137 and 139, exhibited dual inhibitory activities. In particular, 125, 126 and 128 showed selective toxicities against cancer cells. The in vivo animal assay is in progress. 
  Photoprobe 142 was designed based on the structure of 104 and 105. This compound was synthesized and will be used in the photoaffinity labeling experiment in a due course.

Reference ( 163 ) 〈TOP〉

1. (a) Morphy, R.; Kay, C.; Rankovic, Z. Drug Discov. Today 2004, 9, 641–651. From magic bullets to designed multiple ligands. (b) Morphy, R.; Rankovic, Z. J. Med. Chem. 2005, 48, 6523–6543. Designed multiple ligands. An emerging drug discovery paradigm. (c) Morphy, R.; Rankovic, Z. J. Med. Chem. 2006, 49, 4961–4970. The physicochemical challenges of designing multiple ligands.
2. (a) Zimmermann, G. R.; Lehár, J.; Keith, C. T. Drug Discov. Today 2007, 12, 34–42. Multi-target therapeutics: when the whole is greater than the sum of the parts. (b) Keith, C. T.; Borisy, A. A.; Stockwell, B. R. Nat. Rev. Drug Discovery 2005, 4, 71–78. Multicomponent therapeutics for networked systems. (c) O'Boyle, N. M.; Meegan, M. J. Curr. Med. Chem. 2011, 4722–4737. Designed multiple ligands for cancer therapy.
3. (a) Petrelli, A.; Giordano, S. Curr. Med. Chem. 2008, 15, 422–432. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. (b) Gottesman, M. M. Annu. Rev. Med. 2002, 53, 615–627. Mechanisms of cancer drug resistance. (c) Sawyers, C. L. Nature 2007, 449, 993–996. Cancer: mixing cocktails.
4. Simon, F. Nat. Rev. Drug Discovery 2006, 5, 881–882. The trouble with making combination drugs.
5. Edwards, I. R.; Aronson, J. K. Lancet 2000, 356, 1255–1259. Adverse drug reactions: definitions, diagnosis, and management.

Altmetrics

〈TOP〉

E-mail ：

When an article is available to download, a notice will be sent to your mailbox address.

E-mail ：